Nanoemulgel: a novel nano carrier as a tool for topical drug delivery
Nano-emulgel is an emerging drug delivery system intended to enhance the therapeutic
profile of lipophilic drugs. Lipophilic formulations have a variety of limitations, which includes …
profile of lipophilic drugs. Lipophilic formulations have a variety of limitations, which includes …
[HTML][HTML] Advances on plant extracts and phytocompounds with acetylcholinesterase inhibition activity for possible treatment of Alzheimer's disease
Background Alzheimer's disease (AD) is a neurodegenerative disease caused by the
formation of amyloid-beta (Aβ) plaques and neurofibrillary tangles. Acetylcholinesterase …
formation of amyloid-beta (Aβ) plaques and neurofibrillary tangles. Acetylcholinesterase …
[HTML][HTML] Alzheimer's disease current therapies, novel drug delivery systems and future directions for better disease management
Abstract Alzheimer's disease (AD), is a neurodegenerative disorder that escalates with time,
exerting a significant impact on physical and mental health and leading to death. The …
exerting a significant impact on physical and mental health and leading to death. The …
Low-density lipoprotein nanomedicines: mechanisms of targeting, biology, and theranostic potential
Native nanostructured lipoproteins such as low-and high-density lipoproteins (LDL and
HDL) are powerful tools for the targeted delivery of drugs and imaging agents. While the …
HDL) are powerful tools for the targeted delivery of drugs and imaging agents. While the …
Therapeutic nanotechnologies for Alzheimer's disease: A critical analysis of recent trends and findings
Alzheimer's Disease (AD) is an irreversible neurodegenerative disease for which no
modifying therapies are presently available. Besides the identification of pathological …
modifying therapies are presently available. Besides the identification of pathological …
Neuroprotective efficacy of co-encapsulated rosiglitazone and vorinostat nanoparticle on streptozotocin induced mice model of Alzheimer disease
Anomalies in brain insulin signaling have been demonstrated to be involved in the
pathology of Alzheimer disease (AD). In this context, the neuroprotective efficacy of an …
pathology of Alzheimer disease (AD). In this context, the neuroprotective efficacy of an …
Disease‐modifying treatment with I2 imidazoline receptor ligand LSL60101 in an Alzheimer's disease mouse model: a comparative study with donepezil
F Vasilopoulou, S Rodríguez‐Arévalo… - British Journal of …, 2021 - Wiley Online Library
Background and Purpose The development of effective therapeutic strategies against
Alzheimer's disease (AD) remains a challenge. I2 imidazoline receptor ligands have a …
Alzheimer's disease (AD) remains a challenge. I2 imidazoline receptor ligands have a …
PEGylated Polymer–Lipid Hybrid Nanoparticles to Enhance In Vivo Exposure and Uptake of Repaglinide in Brain Cells to Treat Diabetes-Linked Neurodegenerative …
Repaglinide (REP), an antidiabetic drug, is recently explored in ameliorating
neurodegenerative disorders (Huntington's and Alzheimer's disease) by targeting neuronal …
neurodegenerative disorders (Huntington's and Alzheimer's disease) by targeting neuronal …
MiR-130a-3p has protective effects in Alzheimer's disease via targeting DAPK1
Y Wang, M Shi, Z Hong, J Kang… - American Journal of …, 2021 - journals.sagepub.com
The present study investigated the role and potential mechanisms of miR-130a-3p in AD. SH-
SY5Y cells were treated with Aβ 1-42 to construct AD cell models. APP/PS1 mice were used …
SY5Y cells were treated with Aβ 1-42 to construct AD cell models. APP/PS1 mice were used …
ApoE3 Anchored Liposomal Delivery of Rivastigmine for Brain Delivery: Formulation, Characterization, and In Vivo Pharmacokinetic Evaluation
Rivastigmine hydrogen tartrate (RHT) is an acetylcholinesterase (AChE) inhibitor used in the
management of Alzheimer's disease (AD). RHT is a BCS class-I drug that undergoes …
management of Alzheimer's disease (AD). RHT is a BCS class-I drug that undergoes …